{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:10Z","timestamp":1786120330494,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/cad.0b013e32834f9801","type":"journal-article","created":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T04:57:53Z","timestamp":1324961873000},"page":"406-416","source":"Crossref","is-referenced-by-count":9,"title":["Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor"],"prefix":"10.1097","volume":"23","author":[{"given":"Weijin","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210227","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3322\/canjclin.56.4.226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates.","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"R2-6-20210227","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.","volume":"68","author":"Philips","year":"2008","journal-title":"Cancer Res"},{"key":"R3-6-20210227","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3748\/wjg.v12.i24.3859","article-title":"High efficient mammalian expression and secretion of a functional humanized single-chain Fvhuman interleukin-2 molecules.","volume":"12","author":"Shen","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R4-6-20210227","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ygyno.2006.05.016","article-title":"Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.","volume":"103","author":"Zhang","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"R5-6-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0169-5002(03)00134-X","article-title":"EGF receptor as a therapeutic target.","volume":"41","author":"Levitzki","year":"2003","journal-title":"Lung Cancer"},{"key":"R6-6-20210227","first-page":"2703","article-title":"Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.","volume":"3","author":"Mendelsohn","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R7-6-20210227","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-6-20210227","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"key":"R9-6-20210227","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"key":"R10-6-20210227","first-page":"597","article-title":"Construction and screening of phage antibody libraries against epidermal growth factor receptor and soluble expression of single chain Fv.","volume":"44","author":"Sheng","year":"2009","journal-title":"Acta Pharm Sin"},{"key":"R11-6-20210227","first-page":"121","article-title":"Enediyne anticancer antibiotic lidamyin: chemistry, biology and pharmacology.","volume":"30","author":"Shao","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"R12-6-20210227","first-page":"336","article-title":"Relationship between the molecular composition of C-1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity.","volume":"30","author":"Shao","year":"1995","journal-title":"Acta Pharm Sin"},{"key":"R13-6-20210227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11427-007-0058-5","article-title":"Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.","volume":"50","author":"Miao","year":"2007","journal-title":"Sci China Ser C-Life Sci"},{"key":"R14-6-20210227","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-09-2699","article-title":"A bispecific enediye-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.","volume":"16","author":"Guo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R15-6-20210227","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/1078-0432.CCR-07-0938","article-title":"A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.","volume":"13","author":"Stish","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R16-6-20210227","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1158\/1078-0432.CCR-06-2454","article-title":"Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.","volume":"13","author":"Stish","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R17-6-20210227","first-page":"724","article-title":"Squalamine treatment of human tumors in nunu mice enhances platinum-based chemotherapies.","volume":"7","author":"Williams","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R18-6-20210227","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.bjc.6602941","article-title":"Nuclear EGFR signaling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.","volume":"94","author":"Lo","year":"2006","journal-title":"Br J Cancer"},{"key":"R19-6-20210227","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.","volume":"360","author":"Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"R20-6-20210227","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.","volume":"22","author":"Crombet","year":"2004","journal-title":"J Clin Oncol"},{"key":"R21-6-20210227","first-page":"843","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.","volume":"27","author":"Melanie","year":"2007","journal-title":"J Clin Oncol"},{"key":"R22-6-20210227","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nm0103-129","article-title":"Engineered antibodies.","volume":"9","author":"Hudson","year":"2003","journal-title":"Nat Med"},{"key":"R23-6-20210227","first-page":"483","article-title":"Microbial biopharmaceuticals and antibody-based drugs-promising for new drug discovery and development.","volume":"38","author":"Zhen","year":"2003","journal-title":"Acta Pharm Sin"},{"key":"R24-6-20210227","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains.","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat Biotechnol"},{"key":"R25-6-20210227","first-page":"675","article-title":"Antibody therapeutics, antibody engineering, and the merits of protein stability.","volume":"11","author":"Demarest","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R26-6-20210227","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-09-2367","article-title":"Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.","volume":"16","author":"Wang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R27-6-20210227","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1039\/c0ib00099j","article-title":"Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evalution.","volume":"2","author":"Frey","year":"2011","journal-title":"Integr Biol"},{"key":"R28-6-20210227","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/bjc.1992.47","article-title":"Molecular and functional characterization of a fusion protein suited for tumor specific prodrug activation.","volume":"65","author":"Bosslet","year":"1992","journal-title":"Br J Cancer"},{"key":"R29-6-20210227","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-06-0059","article-title":"Humanization of the bispecific epidermal growth factor receptor CD3 diabody and its efficacy as a potential clinical reagent.","volume":"12","author":"Asano","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R30-6-20210227","first-page":"1179","article-title":"The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA suppresses growth of a highly metastatic pancreatic carcinoma cell line.","volume":"23","author":"Bruell","year":"2003","journal-title":"Int J Oncol"},{"key":"R31-6-20210227","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2010.12.001","article-title":"Antibody-dependent cell-mediated cytotoxicity is induced by a single-chain Fv-protein III fusion in the presence of a rabbit anti-protein III polyclonal antibody.","volume":"136","author":"Tsutsumi","year":"2011","journal-title":"Immunol Letters"},{"key":"R32-6-20210227","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/187152008783497055","article-title":"Enediyne anticancer antibiotic lindamycin: chemistry, biology and pharmacology.","volume":"8","author":"Shao","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"R33-6-20210227","first-page":"546","article-title":"Fv-LDP-AE, an engineered and enediyne-energized fusion protein, shows highly potent antitumor efficacy and antiangiogenic activity.","volume":"45","author":"Li","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R34-6-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jbiotec.2009.09.001","article-title":"Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.","volume":"144","author":"Cai","year":"2009","journal-title":"J Biotech"},{"key":"R35-6-20210227","first-page":"582","article-title":"Binding capability of lidamycin apoprotein to human breast cancer detected by tissue microarrays.","volume":"45","author":"Cai","year":"2010","journal-title":"Acta Pharm Sin"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32834f9801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:32:30Z","timestamp":1786048350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201204000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32834f9801","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}